Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma Publisher



Ebadi M1 ; Sadeghi MA2, 3 ; Reddy NM4 ; Rezaei N5, 6, 7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Division of Hematology and Oncology, Department of Pediatrics, University of Minnesota, Minneapolis, MN, United States
  2. 2. Department of Immunology, Molecular Immunology Research Center, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Hematology and Stem Cell Transplantation Section, Division of Hematology/Oncology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, United States
  5. 5. Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran

Source: Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors Published:2020


Abstract

Immunotherapy has been increasingly applied to the treatment of various malignancies in recent decades. Considering the limited clinical effectiveness obtained by other treatment modalities in the treatment of non-Hodgkin lymphoma (NHL), attention has been drawn to immunotherapy as an efficient alternative or complementary therapy. Importantly, the unique immunopathology of NHL makes it quite amenable to immunotherapeutic treatment. This chapter aims to discuss a broad spectrum of these approaches, ranging from monoclonal antibodies (mAbs) which were developed in the early days of immunotherapy to novel techniques developed in just the recent years. Furthermore, various applications of these agents of immunotherapy, both as monotherapy and as combinational therapy, are explored. Since a clear concept of the pathobiology of NHL is necessary for efficient immunotherapy, a brief description with an emphasis on suitable targets for immunotherapy is given before discussing various immunotherapies. © Springer Nature Switzerland AG 2020. All rights reserved.
Related Docs
View other Related Docs
1. Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)
2. Immunopathology and Immunotherapy of Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
3. Immunopathology and Immunotherapy of Hodgkin Lymphoma, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)
4. Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review, Current Cancer Therapy Reviews (2024)
5. The Applications of Anti-Cd20 Antibodies to Treat Various B Cells Disorders, Biomedicine and Pharmacotherapy (2019)
6. Anti-Cd20 Antibody Treatment for B-Cell Malignancies, Resistance to Anti-CD20 Antibodies and approaches for their Reversal: Volume 2 (2023)
7. Chimeric Antigen Receptor -T Cell Therapy: Applications and Challenges in Treatment of Allergy and Asthma, Biomedicine and Pharmacotherapy (2020)
8. Monoclonal Antibodies for Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (27)
Hamid Reza Mirzaei (10)
Other Related Docs
9. Preclinical Studies of Chimeric Antigen Receptor-Modified Natural Killer Cells in Cancer Immunotherapy: A Review, Expert Opinion on Biological Therapy (2022)
10. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells, Frontiers in Immunology (2018)
11. Novel Methods to Improve the Efficiency of Radioimmunotherapy for Non-Hodgkin Lymphoma, International Reviews of Immunology (2019)
12. Car-T Cells: Early Successes in Blood Cancer and Challenges in Solid Tumors, Acta Pharmaceutica Sinica B (2021)
13. Antigen-Independent Killer Cells Prepared for Adoptive Immunotherapy: One Source, Divergent Protocols, Diverse Nomenclature, Journal of Immunological Methods (2020)
14. Car-Modified T-Cell Therapy for Cancer: An Updated Review, Artificial Cells# Nanomedicine and Biotechnology (2016)
15. Neurological Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy, Expert Review of Clinical Immunology (2023)
16. Prolonged Persistence of Chimeric Antigen Receptor (Car) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward, Frontiers in Immunology (2020)
17. Advances in Natural Killer Cell Therapies for Breast Cancer, Immunology and Cell Biology (2023)
18. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
19. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
20. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
21. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
22. Radioimmunotherapy in Non-Hodgkin Lymphoma: Prediction and Assessment of Response, Critical Reviews in Oncology/Hematology (2016)
23. Cell Transfer-Based Immunotherapies in Cancer: A Review, IUBMB Life (2020)
24. Natural Killer Cells and Cancer Therapy, What We Know and Where We Are Going, Immunotherapy (2019)
25. Natural Killer Cell–Based Immunotherapy: From Transplantation Toward Targeting Cancer Stem Cells, Journal of Cellular Physiology (2018)
26. Novel Car T Therapy Is a Ray of Hope in the Treatment of Seriously Ill Aml Patients, Stem Cell Research and Therapy (2021)
27. Car-Nk Cell: A New Paradigm in Tumor Immunotherapy, Frontiers in Oncology (2021)
28. A Deep Insight Into Crispr/Cas9 Application in Car-T Cell-Based Tumor Immunotherapies, Stem Cell Research and Therapy (2021)
29. The Paths and Challenges of “Off-The-Shelf” Car-T Cell Therapy: An Overview of Clinical Trials, Biomedicine and Pharmacotherapy (2023)
30. Hurdles in Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
31. Biomarkers for Predicting the Outcome of Various Cancer Immunotherapies, Critical Reviews in Oncology/Hematology (2021)
32. Prospects for Chimeric Antigen Receptor (Car) Γδ T Cells: A Potential Game Changer for Adoptive T Cell Cancer Immunotherapy, Cancer Letters (2016)
33. Remote Controlling of Car-T Cells and Toxicity Management: Molecular Switches and Next Generation Cars, Translational Oncology (2021)
34. The Promising Role of Monoclonal Antibodies for Immunotherapy of the Hiv-Associated Cancer, Non-Hodgkin Lymphoma, International Reviews of Immunology (2018)
35. Car-Nk Cells: A Promising Cellular Immunotherapy in Lymphoma, Expert Opinion on Biological Therapy (2023)
36. In Silico Analysis for Determination and Validation of Human Cd20 Antigen 3D Structure, International Journal of Peptide Research and Therapeutics (2019)
37. Antibody-Drug Conjugates: Possibilities and Challenges, Avicenna Journal of Medical Biotechnology (2019)
38. The Current Landscape of Car T-Cell Therapy for Solid Tumors: Mechanisms, Research Progress, Challenges, and Counterstrategies, Frontiers in Immunology (2023)
39. An Updated Overview of the Application of Car-T Cell Therapy in Neurological Diseases, Biotechnology Progress (2023)
40. Cancer Immunotherapy: Diverse Approaches and Obstacles, Current Pharmaceutical Design (2022)
41. Predictive and Therapeutic Biomarkers in Chimeric Antigen Receptor T-Cell Therapy: A Clinical Perspective, Journal of Cellular Physiology (2019)
42. Contribution of Natural Killer Cells in Innate Immunity Against Colorectal Cancer, Frontiers in Oncology (2023)
43. Gene-Knocked Out Chimeric Antigen Receptor (Car) T Cells: Tuning up for the Next Generation Cancer Immunotherapy, Cancer Letters (2018)
44. Recent Progress in Cancer Immunotherapy: Overview of Current Status and Challenges, Pathology Research and Practice (2023)
45. Reinforcing the Primary Immunotherapy Modulators Against Acute Leukemia; Monoclonal Antibodies in Aml, Immunotherapy (2019)
46. Radioimmunotherapy As the First Line of Treatment in Non-Hodgkin Lymphoma, Immunotherapy (2018)
47. Car-Engineered Nk Cells; a Promising Therapeutic Option for Treatment of Hematological Malignancies, Stem Cell Research and Therapy (2021)
48. B Cells in Multiple Sclerosis Therapy—A Comprehensive Review, Acta Neurologica Scandinavica (2018)
49. Solid Tumors Challenges and New Insights of Car T Cell Engineering, Stem Cell Reviews and Reports (2019)
50. A Metabolic Switch to Memory Car T Cells: Implications for Cancer Treatment, Cancer Letters (2021)